Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. There are two major histopathological types of RMS -embryonal (eRMS) and alveolar (aRMS). A molecular study of Igf2, MyoD1 and Myogenin was performed to determine the expression profiles and to assess the possible utility of these genes as potential treatment targets. Patients with RMS showed up to 100-fold increase of Igf2 transcription in comparison with normal skeletal muscle. Our data suggest that overexpression of Igf2 occurs in RMS of both histological subtypes. No correlation between the results of Igf2 mRNA expression and LOH at the 11p15 region (p= 0.12) was observed, but there was a trend of a higher expression of Igf2 mRNA in RMS samples with LOH.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. The tumor accounts for approximately two thirds of all sarcomas of children aged 0 -14 years, and approximately for 8 % of malignant solid tumors in childhood [1] .
RMS is of mesenchymal origin and may arise virtually anywhere in the body. Its diagnosis is based on identification of rhabdomyoblastic differentiation of tumor cells. There are two major histopathological types of RMS commonly seen in pediatric practice -embryonal (eRMS) and alveolar (aRMS). In 60 to 70 % of aRMS one of two characteristic chromosomal translocations are found: t(2;13)(q35;q14) involving PAX3 gene at 2q and FKHR gene at 13q or a variant translocation t(1;13)(q36;p14) which fuses PAX7 gene with FKHR [2] . These translocations result in an alteration of biological activity at protein level and are thought to influence tumorigenic behavior having impact on control of the tumor cell growth, apoptosis, differentiation and motility [3] . No primary molecular genetic aberration analogous to the FKHR rearrangement has been detected in eRMS. A high frequency of loss of heterozygosity (LOH) at a chromosomal region 11p15, a region known to contain several imprinted genes including insulin-like growth factor 2 (Igf2), H19 and p57 KIP2 , has been found in eRMS [4] , but other studies have shown that both eRMS and aRMS are associated with LOH and loss of imprinting (LOI) of genes mapping to 11p15 [5] . Moreover, alteration of the imprinting of the Igf2 gene has been published in Wilm´s tumor, and RMS with retention of heterozygosity (ROH) in 11p15 were identified [6, 7, 8] . These findings support a notion that maternal-specific LOH and LOI of Igf2 are alternative pathways contributing to tumorigenesis through the up-regulation of IGF2.
Insuline-like growth factor 2 (IGF2) has been shown to play an important role in the development, growth, and survival of normal cells. IGF2 is encoded by the imprinted Igf2 gene expressed only from the paternal allele in most tissues [8] . Overexpression of Igf2 has been observed in several types of sporadic human neoplasms and this phenomenon has been attributed to loss of imprinting of the maternal allele [9, 10] . Consequently, LOI of Igf2 has been proposed as an important mechanism of tumorigenesis. Overexpression of Igf2 may be caused also by uniparental disomy involving duplication of the paternal (non-imprinted) locus, and loss of the maternal (imprinted) locus [9] . Alternatively, increased Igf2 transcription could reflect amplification of the Igf2 gene in the tumor or Igf2 might become a target of abnormally activated signaling pathways. For example, Khan et al found that PAX3-FKHR in aRMS but not PAX3 alone is able to activate a number of genes, including Igf2 and activates myogenic transcriptional program including induction of MyoD1 transcription, Myogenin and Six1 as well as a number of other muscle-specific genes [11] . A role of IGF2 in myogenic differentiation has been demonstrated by identifying this peptide as an autocrine differentiation factor in myoblasts [12] as well as a survival factor during the transition from proliferating to differentiating myoblasts [13] . IGF2 overexpressing myoblasts undergo enhanced differentiation characterized by accelerated expression of Myogenin mRNA and extensive myotube formation [14] .
The basic helix-loop-helix transcription factors of the MyoD family (MyoD, myf-5, Myogenin, MRF4) play a central role in myogenesis [15] . Many studies have demonstrated that these proteins individually can convert uncommitted mesenchymal precursors to the myoblastic lineage [16] . MyoD and myf-5 are essential for myoblast specification during early embryonic development [17] , Myogenin is critical for the cell differentiation [18] and MRF4 plays a secondary role in muscle formation [19] .
The myogenic determination (MyoD) gene was first identified by virtue of its ability to convert nonmuscle cells into muscle cells [20] . Myogenin gene is a direct transcriptional target of MyoD [15] . Activation of Myogenin gene transcription occurs as a very early event in MyoD-regulated muscle differentiation, and it is preceded by the accumulation of key regulatory proteins, including MyoD at the proximal Myogenin promoter.
The study of Wilson and Rotwein shows that inhibition of Igf2 expression in differentiating myoblasts blocked reversibly MyoD-mediated muscle differentiation [15] . Blockade of this pathway inhibits stimulation of Myogenin gene expression, and prevents morphological differentiation. The absence of IGF2 signaling did not change the abundance of MyoD1 in the nucleus or at the Myogenin promoter.
To investigate the potentional importance of IGF2 in pathogenesis of RMS of both alveolar and embryonal subtypes we analyzed tumor material and correlated histotype with the presence of characteristic translocations and expression status of Igf2, MyoD1 and Myogenin, as well as LOH of 11p15.
Materials and methods
Sample collection and patients samples. There were 35 boys and 35 girls in the study group. Histologically, 42 patients were diagnosed with alveolar and 28 with embryonal RMS. Twenty six patients with alveolar RMS had chimeric products identified (21 PAX3-FKHR and 5 PAX7-FKHR). 16 cases with alveolar morphology were fusion gene negative aRMS - Table 1a . Eleven patients with aRMS had favorable localization of the primary tumor and 31 had unfavorable primary sites (parameningeal, extremity and genitourinary -bladder or prostate). Similarly, 13 patients with eRMS had favorable and 15 unfavorable localizations of tumors. Samples of bone marrow or peripheral blood progenitor cells were collected in EDTA at the time of the tumor diagnosis and, in some cases, during chemotherapy. The tumors were diagnosed by light microscopy using hematoxylin and eosin staining complemented by immunohistochemistry. A panel of primary antibodies included vimentin (dilution 1:100, DAKO -clone V97), desmin (dilution 1:100, DAKO -clone D33), sarcomeric actin (dilution 1:75, DAKO -clone Alpha-Sr-1), MyoD1 protein (dilution 1:50, DAKO -clone 5.8A), myogenin (dilution 1:30, DAKO -clone F5D) and anti CD99 (dilution 1:500, Lab Vision -clone O13).
To determine the specificity of Igf2, MyoD1 and Myogenin for RMS at the molecular level we analyzed a group of neoplasms other than RMS - Table 1b .
RNA extraction and preparation of complementary DNA (cDNA). RNA was extracted from 10 x 5µm thick sections of the tumor tissue or from bone marrow samples using TriReagent (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instructions. Forty four samples obtained from various non-neoplastic tissues or neoplasms were extracted using the same protocol (Table 1b) .
Complementary DNA was prepared from 1 µl of RNA in 20 µl of reaction volume. The protocol was described by Krsková et al [21] .
Quantitative RT-PCR for fusion gene PAX3-7/FKHR, Igf2, Myogenin and for MyoD1 was performed on LightCycler (Roche), using TaqMan technology. Primers and probes are listed in the Table 2 . PAX3/FKHR and PAX7/FKHR primers and probes for RQ-RT-PCR were designed by TipMolBiol, MyoD1 primers and probe was obtained from Applied Biosystems. For the Myogenin and Igf2 gene expression measurement, we applied RQ-RT-PCR with LNA probe generated by means of the Universal Probe Library for Human found at the website www.universalprobelibrary.com (Roche, Manheim, Germany). Human Beta 2 microglobulin (β2M) was used as a housekeeping gene [22] . Amplifications of both fusion transcripts and MyoD1 were under identical PCR conditions on LightCycler. cDNA was amplified with a mix consisting of: Platinum Taq Polymerase 1 U in the PCR buffer provided by the manufacturer (Gibco BRL), 4.5 mM MgCl 2, 0.2 mM each dNTP, 0.25 µg/µl BSA, 0.5 µM of each primer, 0.2 µM of hydrolyzation probe, 1 µl of cDNA in a final volume of 20 µl. The reaction mixture was subjected to denaturation at 95 °C for 90s followed by 50 cycles of rapid amplification -denaturation at 95°C for 10s, annealing at 60 °C for 35s on LightCycler (Roche, Mannheim, Germany).
Amplification of Myogenin was under the following PCR conditions on LightCycler. The PCR mix was composed of Platinum Taq DNA Polymerase (1 unit in the PCR buffer provided by the manufacturer, Gibco BRL, Carlsbad, Tex); MgCl 2 (3.5 mM), dNTPs (0.2 mM each); BSA (0.25 µg/µl); primers (0.2 µM each); probe (0.1 µM) and cDNA (1 µl) in a final volume of 20 µl. The program consisted of incubation at 40 °C for 2 minutes and initial denaturation at 95 °C for 2 minutes, followed by 45 cycles at 95 °C for 10 sec., and 60 °C for 35 sec (single fluorescence measurement).
For Igf2 expression measurement we applied single-round RQ-RT-PCR in SYBR Green format with primers described by Zhan et al [7] (sequencies in the Table 2 ).The mix for Igf2 quantification was as follows: Platinum Taq DNA Polymerase (1 unit in the PCR buffer provided by the manufacturer, Gibco BRL, Carlsbad, Tex); MgCl 2 (4.5 mM), dNTPs (0.2 mM each); BSA (0.25 µg/µl); primers (0.5 µM each); 2µl of 5x10 -4 SYBR Igf2 and MyoD1 sequences were cloned into a PCR 2.1 TOPO cloning vector and were transformed into E. coli recipient culture, using the TOPO TA Cloning Kit (Invitrogen). The selected clones were screened using Miniprep method and quantified using spectrophotometer.
Normalization of β2-microglobulin and fuse genes, Myogenin, Igf2 or MyoD1 expression. The expression of all genes was calculated using absolute quantification. Plasmids with the insert were diluted in decimal steps into Salmon Sperm DNA. A diluting line of plasmids was used for preparation of standard curves. Normalized expression (MyoD1 N , Myogenin N , Igf2 N or PAX3/7-FKHR N ) was determined as a ratio between gene transcript and β2-microglobulin levels.
Each PCR run was performed in duplicate and the mean value of results was calculated.
LOH study. The presence of LOH was studied in 42 patients´ samples obtained from the tumors at the time of diagnosis, or from recurrent lesions. Each sample was compared with constitutional DNA of the same patient obtained from bone marrow aspirate or from peripheral blood. All constitutional samples were without tumor cell contamination as confirmed by molecular techniques (negative results of RT-PCR for MyoD1, α/γ acetylcholine receptor, PAX3/FKHR and PAX7/FKHR).
Polymorphic STR markers. A panel of 6 highly informative microsatellite markers was used. Table 3 shows a list of these markers.
Amplification was performed with primers labeled with fluorescent dye (6-FAM) in a final volume 20 µl containing 50 -100 ng of DNA template, 1-2 mM MgCl 2 , 10 pM of each primer, 0.2 mM dNTPs, 1 x reaction buffer, and 0.3 U Taq polymerase (Top-Bio, Prague, Czech Republic). Amplification was performed in an automated thermal cycler with 5 min 95 °C denaturation step followed by 30 cycles of 94 °C denaturation 30 sec, annealing at the temperature 60 -66 °C for 45 sec, and extension at 72 °C 30 sec. The last cycle was followed by a final extension at 72°C for 20 min. PCR products were detected by fragment analysis using an automated genetic analyzer ABI PRISM 310 (Applied Biosystems, Foster City, California, USA).
Statistical analysis. We used the JMP IN 5.1 software (SAS Institute, Cary, NC, USA). To establish whether mRNA differences were significant a non-parametric one-way analysis of variance, the Kruskal-Wallis or Mann-Whitney tests were utilized. RQ-RT-PCR correlations were measured with Spearman's coefficient of correlation. For all tests, p < 0.05 was considered significant.
Results
LOH study. We screened 42 paired tumor / peripheral blood or bone marrow samples without tumor cell contamination for LOH from 14 patients with eRMS and 28 patients with The frequency of LOH on 11p from telomere to 11p14 was as follows: D11S1363 54,5% -THO 50% -D11S1338 37,5% -D11S1307 54% -D11S921 42% -D11S1888 27% in patients with aRMSs, and D11S1363 100% -TH 67% -D11S1338 67% -D11S1307 43% -D11S921 25% -D11S1888 57% in patients with eRMSs. The last three microsatellite markers (D11S1307, D11S921, D11S1888) from the region 11p15 map close to the MyoD1 gene, which is a regulatory factor of muscle differentiation and a molecular marker of RMS. The frequency of LOH in this region was surprisingly high, which suggests that this region of LOH includes the MyoD1 locus.
The level of Igf2 mRNA in RMS. We did not observe any statistical difference in the level of Igf2 N mRNA in the two subgroups of RMS. The median of Igf2 N mRNA for PAX3-FKHR positive aRMS was 1.92x10 9 , mean value 6.13x10 9 ; the median of Igf2 N mRNA for PAX7-FKHR positive aRMS was 1.77x10 9 , mean value 2.12x10 9 ; the median of Igf2 N mRNA for fusionnegative aRMS was 1.11x10 9 , mean value 3x10 9 . For eRMS the median value was 1.64 x10 9 , mean 1.77x10 10 . A statistical analysis of different control tumors (Tab. 1b) using the nonparametric Kruskal-Wallis test showed significantly different mRNA level of Igf2 between RMS and the control group of tumors (p<0.0001) -Fig 1. Additionally, we showed 100-fold higher level of Igf2 mRNA in RMS than in muscle specimens (median value was 4.1 x10 7 , mean 1.78x10 8 ).
We observed a high level of Igf2 mRNA in both aRMS and eRMS (p=0.54) and in both PAX/FKHR fusion products (p=0.58). No correlation was observed between the results of Igf2 mRNA expression and age (p= 0.48), sex (p=0.43), metastases (p=0.86), relapse of the disease (p=0.23). The correlation was observed between the results of Igf2 mRNA expression and localization of the primary tumor -favorable or unfavorable (p= 0.011). No correlation was observed between the results of Igf2 mRNA expression and LOH at the region (p= 0.12).
The level of MyoD1 mRNA in RMS. We did not observe any statistical difference in the level of MyoD1 N mRNA in subgroups of RMS. The median of MyoD1 N mRNA for fusionpositive aRMS was 1. ). We observed a high level of MyoD1 mRNA in both PAX/ FKHR fusion products (p=0.72). The relation between age and generalization of the disease at diagnosis (the two principal risk factors of RMS) and MyoD1 expression in the primary tumor samples was analyzed. In children at different age groups no major difference in MyoD1 expression was observed (p>0.05). A similar finding was observed for groups of localized and metastatic RMSs (p=0.31). No correlations were observed between the results of MyoD1 mRNA expression and sex (p=0.53), localization of the primary tumor -favorable or unfavorable (p=0.25), relapse of the disease (p=0.39) and survival (p=0.65). The correlation was observed between the ; the median of Myogenin N mRNA for PAX7-FKHR positive aRMS was 6,63x10 5 , mean value 1.21x10 6 , the median of Myogenin N mRNA for fusion-negative aRMS was 2.3x10 6 , mean value 3.84x10 6 , and for eRMS the median value was 9.75 x10 5 , mean 5.71x10 6 . We observed a similar level of Myogenin mRNA in RMS and normal skeletal muscles (median value was 7.2 x10 6 , mean 6.97x10 6 ). We observed a high level of Myogenin mRNA in both aRMS and eRMS (p=0.17) and a higher level in RMS with PAX3/FKHR fusion product than in PAX7/FKHR fusion product (p=0.027). No correlations were observed between the results of Myogenin mRNA expression and age (p=0.32), sex (p=0.60), and relapse of the disease (p=0.13). We observed a trend of a higher level of Myogenin mRNA as compared with localization of the primary tumor -favorable or unfavorable (p= 0.064), and a generalized disease at the time of presentation (p=0.068) and a relapse (p=0.18). No correlation was observed between the results of Myogenin mRNA expression and LOH at the 11p15 region (p= 0.56).
The high level of Myogenin mRNA correlated with Igf2 mRNA level (p=0.008) and MyoD mRNA level (p<0.0001).
Specificity of PAX3/7-FKHR fusion gene for aRMS. PAX3-FKHR or PAX7-FKHR transcripts were found specific for aRMS. We did not find PAX3/7-FKHR positivity in any of non-RMS tumors. The median of PAX3-FKHR N mRNA for aRMS was 1.18x10 5 , mean value 6.11x10 5 , and median of PAX7-FKHR N mRNA for aRMS was 2.75x10 3 , mean value 6.26x10 3 .
Discussion
Genomic imprinting is the preferential way of silencing one parental allele due to epigenetic modifications. Insulin-like growth factor 2 (Igf2), which codes for a potent mitogen [23, 24] , is an imprinted gene located at chromosome 11p15.5 in human. In most tissues Igf2 is maternally imprinted. Loss of Igf2 imprinting commonly occurs in various tumors, and it may be involved in malignant transformation [25, 26] . Igf2 loss of imprinting leads to biallelic production of IGF2 protein.
IGF2 is an important fetal growth stimulatory factor and it is involved in RAS-RAF-MAPK cascade and in the PI3 cascade whose activation results in both cell cycle progression and protection from apoptosis. IGF2 appears to be important for growth of osteosarcoma; suppression of IGF2 in osteosarcoma cell lines leads to growth inhibition [27] . Similarly, our results point out to an important role of Igf2 overexpression in the pathogenesis of RMS. Because IGF2 is indispensable for tumor transformation of RMS, we aimed to determine the mechanism involved in Igf2 overexpression. Igf2 transcripts were quantified using TaqMan assay. Patients with RMS showed up to 100-fold increase of Igf2 transcription in comparison with normal skeletal muscle. Our data suggest that overexpression of Igf2 occurs in RMS of both histological subtypes and both in the absence or in the presence of the tumor specific translocations. Possible mecha- nisms of Igf2 overexpression could rest in uniparental disomy, polyploidy or in loss of imprinting. Increased IGF2 expression could also reflect amplification of the Igf2 gene in the tumor or, alternatively, Igf2 may become a target of an abnormally activated PTCH signaling pathway [28] Uniparental disomy is caused by a loss of the maternal (imprinted) Igf2 locus with a concomitant duplication of the paternal Igf2 locus. In our study no correlation was observed between the results of Igf2 mRNA expression and LOH at the 11p15 region (p= 0.12), but with a trend of a higher expression of Igf2 mRNA in RMS samples with LOH at the 11p15.5 region. These data provided support for the potential role of LOH with uniparental disomy in overexpression of Igf2 in a significant proportion of our RMS patients. The findings of Minniti et al. show that unregulated overexpression of IGF2 growth factor interferes with myogenic differentiation as defined by a lack of myotube formation and a decrease in the expression of Myogenin [29] . In our study we found a 100-fold higher level of Igf2 mRNA in patients with RMS than in non-neoplastic muscle specimens, but a very similar level of MyoD1 and Myogenin mRNAs in both RMS and normal muscles.
Khan et al. found that PAX3-FKHR but not PAX3 alone was able to activate a number of genes, including Igf2 [11] . We observed a high level of Igf2 mRNA in both aRMS and eRMS (p=0.54) and in both PAX/FKHR fusion products (p=0.58). We can, therefore, speculate that Igf2 gene is not a candidate downstream target of PAX3-FKHR pathway in aRMS.
A high percentage of LOH was identified on chromosome 11p. These results suggest the presence of either a cluster of tumor suppressor genes or a single pleiotropic gene involved in tumorigenesis localized at 11p15. Moreover, the obtained data indicate that the critical region is centered between the loci D11S1363 and D11S1338. Since LOH in 11p15.5 has been demonstrated in eRMS [30, 31] , our results from LOH study show, that both alveolar and embryonal subtypes of RMS have alterations at this region. Our data also show similar frequency of LOH in eRMS (78.5%) and fusion negative aRMS patients (83 %) in contrast to fusion negative aRMS (45 %). These data are in conclusion with the study of Davicioni et al, who stated that fusion negative aRMS is more similar to eRMS than to fusion positive aRMS [34] . Also array comparative genomic hybridization (aCGH) indicated that the frequency of a number of gains, amplifications and losses is significantly different between fusion positive aRMS and fusion negative aRMS and eRMS [32] . Williamson et al. demonstrated that fusion negative aRMS is not readily distinguishable from eRMS and that the primary influence on the clinical presentation, outcome and molecular biology of RMS is the presence or absence of a fusion gene [32] .
We found LOH between the loci D11S1307 and D11D921 where the gene MyoD1 maps. The frequency of LOH in this region was surprisingly high, which suggests that this common region of LOH includes the MyoD1 locus. MyoD1 (myogenic determination) gene codes for a regulatory factor of muscle differentiation and it is considered a molecular marker of RMS [31, 33] . We found a high level of MyoD1 mRNA in correlation with LOH at the 11p15 region (p= 0.019) - Fig.2 .
Davicioni et al. reported that MyoD1 is a PAX/FKHR target gene and that it was expressed in a two-fold higher amount in PAX-FKHR transduced embryonal cell line RD compared with vector control [34] . In contrast to this finding, we did not observe any significant difference between expression levels of MyoD1 in all subgroups of RMS (both the chimeric gene positive and negative).
In accordance with observations published by Gattenloehner et al. we found that MyoD1 transcript is not entirely specific for RMS [2] . We found MyoD1 transcripts in a normal skeletal muscle, a result similar to that seen in aRMS and eRMS. Furthermore, other mesenchymal neoplasms used as a control tissue revealed MyoD1 N expression (median 1. In this study we may confirm recent observations showing that there are differences between a strong and uniform pattern of Myogenin positivity in alveolar RMSs whereas the pattern in embryonal RMS is more heterogeneous [35, 36, 37] . In contrast to the results of immunohistochemistry demonstrating the protein, RQ-RT-PCR data did not reveal different levels of Myogenin mRNA in aRMSs and eRMSs. We observed a higher level of Myogenin in PAX3/FKHR fusion product in comparison with PAX7/FKHR fusion product (p=0.027). It could be caused by an increased transcriptional potency of PAX3/FKHR fusion transcript relative to that of PAX7/FKHR, and it may result in the fact that the tumors with the PAX7/FKHR fusion transcript appear to have a more favorable prognosis [38, 39] . This result also suggests that high expression of PAX3-FKHR and Igf2 in fusion positive aRMS patients could synergistically play a role in oncogenesis and tumor progression of aRMS. In this study we demonstrated the trend of a higher level of Myogenin mRNA in comparison with localization of the primary tumor -favorable or unfavorable (p=0.064), with a generalized disease at the time of presentation (p=0.068), and the disease relapse (p=0.046). No correlation was observed between the results of Myogenin mRNA expression and LOH at the 11p15 region (p=0.56). The high level of Myogenin mRNA correlated well with Igf2 mRNA level (p=0.008) and MyoD mRNA level (<0.0001). It is probably caused by the mechanism in which MyoD1, and consequently Myogenin, are downstream targets of Igf2 pathway in both aRMS and eRMS.
Our data demonstrate, that Myogenin transcript is not entirely specific for RMS. We found Myogenin transcripts in a normal skeletal muscle (median 7.2x10 6 ), a result similar to that seen in aRMS and eRMS. Furthermore, other mesenchymal neoplasms used as a control tissue revealed Myogenin N expression (median 4.93x10 4 , mean value 3.28x10 5 ). Some non-Hodgkin's lymphomas (NHLs) show also Myogenin N expression, though weak (median 1.23x10 0 , mean value 1.15x10 1 ). The positivity of MyoD1 and Myogenin in other tumors is difficult to explain. These data could indicate that both MyoD1 and Myogenin may play a role as transcriptional factors not only in myogenesis.
Future studies of aRMS and eRMS should provide a clearer understanding of translocation-dependent or independent pathways for development of aRMS and the nature of the constitutional molecular changes in eRMSs.
